Trial Profile

Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FCR 001 (Primary)
Indications Renal transplant rejection
Focus Therapeutic Use
Sponsors Talaris Therapeutics

Most Recent Events

28 Jun 2023 Results of immunocompetence and biomarkers of tolerance in chimeric and immunosuppression- free kidney allograft recipients, published in the Transplantation
03 May 2023 Status changed from active, no longer recruiting to discontinued.
07 Nov 2022 According to a Talaris Therapeutics media release, data from the trial was presented at the 2022 American Society of Nephrology (ASN) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com